Elouen Boughalem
Institut de Cancérologie de l'Ouest(FR)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Bladder and Urothelial Cancer Treatments, Renal cell carcinoma treatment, Urinary and Genital Oncology Studies, Prostate Cancer Treatment and Research
Most-Cited Works
- → Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial(2023)95 cited
- → Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective study(2020)24 cited
- → Is there a withdrawal syndrome with abiraterone acetate (AA)?(2013)10 cited
- → Frontline immune checkpoint inhibitor-based combination therapy in metastatic renal cell carcinoma patients with poor performance status(2022)9 cited
- → Long survival of patients with metastatic clear cell renal cell carcinoma. Results of real life study of 344 patients(2019)9 cited
- → Cabazitaxel multiple rechallenges in metastatic castration‐resistant prostate cancer(2021)9 cited
- → Are immune checkpoint inhibitors (ICI) a valid option for papillary renal cell carcinoma (pRCC)? A multicenter retrospective study.(2019)6 cited
- → Chemotherapy following immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinoma(2022)6 cited
- → Efficacy of first-line combination therapy in metastatic renal cell carcinoma (mRCC) patients (pts) with poor performance status (PS).(2022)3 cited
- → Patient Versus Clinician Reported Symptoms Agreement in Advanced Metastatic Bladder Cancer Patients(2025)2 cited